Search results | personalized medicine

Reports

Personalized Medicine in Oncology Partnering Terms and Agreements

The Personalized Medicine in Oncology Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the personalized medicine in oncology partnering agreements entered into by the worlds leading healthcare companies.

Personalized Medicine Partnering Terms & Agreements

Comprehensive understanding and unprecedented access to the personalized medicine partnering deals and agreements entered into by the worlds leading healthcare companies.

Insights

Personalized medicine

Personalized medicine proposes customization of healthcare – with medical decisions, practices, and/or…

Personalized medicine: recent life science partnering trends

Recent advances in biomarkers, pharmacogenomics, and companion diagnostics have increased partnering trends and opportunities in the emerging field of personalized medicine.

Personalized medicine in oncology: recent life science partnering trends

Scientists predict that the cure to cancer in the future lies in exploiting personalized medicine technology.

What attracts venture capitalists in personalized medicine financing?

Companies like Starbucks, Amazon.com and Apple aren’t healthcare companies, but one venture capitalist believes their example can guide personalized medicine

Roche seeks to dominate personalized medicine: bids $5.7 billion for Illumina

Roche has made a hostile bid of $5.7 billion for Illumina, a leading provider of genetic analysis services, by going straight to shareholders after failing to convince the company’s management to accept their offer

Recent trends in personalized medicine: oncology deal-making

An article by Steve Poile on personalized medicine deal-making.

Novartis eyes for more pharma deals in Israel

Novartis , the world’s biggest pharmaceutical (big pharma) company, recently increased its interest in Israel to sign pharma deals. For a long time, the company was active in marketing and clinical trials in Israel, and now it is involved in investment as well.

Chugai Pharmaceutical Ltd – Japan’s number one biopharmaceutical company

Chugai Pharmaceutical manufactures, sells, imports and exports pharmaceuticals and has become the leading biopharmaceutical company in Japan.

Current Agreements Deal Analysis Update : November 2014

This month we provide you with an overview of deal analysis in the life science sectors, covering partnering, M&A and financing in October 2014.

Current Agreements Deal Analysis Update : August 2014

This month we provide you with a deal analysis  overview of life science partnering, M&A and financing in July 2014.

Events

Sorry, your search returned no results.


Deals

What attracts venture capitalists in personalized medicine financing?

Companies like Starbucks, Amazon.com and Apple aren’t healthcare companies, but one venture capitalist believes their example can guide personalized medicine

Roche and Foundation Medicine in personalized meds for cancer pact

Foundation Medicine and Roche enter into a broad strategic collaboration to further advance Foundation Medicine’s market-leading position in molecular information and genomic analysis

AstraZeneca pharma partners Sarah Cannon Research Institute for personalized oncology medicine

Sarah Cannon Research Institute and pharma partners AstraZeneca announced a collaboration in the field of personalized medicine to support development of new AstraZeneca oncology compounds.

Genzyme and Veracyte announce global co-promotion agreement to deliver personalized solution for thyroid patients

Genzyme and Veracyte announced a global co-promotion partnership to provide a comprehensive solution for thyroid patients. The arrangement will give patients worldwide increased access to an advanced personalized medicine solution for improved diagnosis of thyroid nodules, and the potential to significantly reduce the number of unnecessary thyroidectomies.

Ventana signs collaboration with big pharma Merck

Ventana Medical Systems has entered into an agreement with, big pharma, Merck KGaA to collaborate on the development and commercialization of a companion diagnostic (CDx) for an undisclosed target using Ventana’s proprietary diagnostic assays.

Research, licensing and joint development agreement for imaging flow technology platform

EMD Millipore announced a clinical research, licensing and joint development agreement with Sysmex Corporation of Japan.

Licensing agreement for patient-derived xenograft mouse models

WuXi PharmaTech announced a licensing agreement with Mayo Clinic’s Center for Individualized Medicine to expand WuXi’s collection of patient-derived xenograft (PDX) mouse models.

Boehringer Ingelheim signs biotech deals with Ventana for oncology programs

Ventana Medical Systems have signed biotech deals to collaborate on the development of companion diagnostic tests for Boehringer Ingelheim oncology programs

Amgen big pharma partners Transgenomic for CE-IVD test collaborative R&D

Pharma partners, Transgenomic and Amgen have entered into a collaborative R&D agreement to develop a CE-IVD test to screen patients with metastatic colorectal cancer for RAS mutations.

Thermo Fisher acquires Life Technologies for $13.6 billion

Thermo Fisher acquires rival in Gene Sequencing Equipment, Life Technologies, for $13.6 billion